Ultragenyx Pharmaceutical (UP0) Price & Analysis

2 Followers

UP0 Stock Chart & Stats

€21.53

-€0.38(-1.59%)

At close: Jul 24 4:00 PM EDT

€21.53

-€0.38(-1.59%)

Day’s Range― - ―

52-Week Range€11.19 - €34.00

Previous CloseN/A

Volume0.00

Average Volume (3M)35.00

Market Cap

€1.52B

Enterprise Value€4.31B

Total Cash (Recent Filing)€292.00M

Total Debt (Recent Filing)€1.20B

Price to Earnings (P/E)―

Beta0.88

Next Earnings

Nov 03, 2026

EPS Estimate

-0.99

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.84

Shares Outstanding98,588,875

10 Day Avg. Volume10

30 Day Avg. Volume35

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)-28.35

Price to Sales (P/S)3.37

P/FCF Ratio-4.80

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€23.60

Price Target Upside9.60% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering21

EPS Forecast (FY)-4.15

Revenue Forecast (FY)€676.22M

Bulls Say, Bears Say

Bulls Say

Revenue Scale And Gross MarginRapid multi-year revenue expansion and consistently high gross margins show that Ultragenyx has built meaningful commercial scale in rare diseases. This provides a strong base for reinvestment, supports attractive product economics, and creates operating leverage if expense growth moderates.

Expanding Commercial Rare-disease PortfolioRevenue is distributed across several approved therapies rather than relying solely on a single launch, while Evkeeza is showing strong growth. Broad product adoption across geographies and patient populations can improve commercial durability and support sustained expansion.

Regulatory Achievements And Non-dilutive FundingFAYUVI approval expanded the commercial rare-disease franchise and generated a valuable regulatory asset that the company is monetizing for substantial cash. Such non-dilutive funding can improve flexibility to support launches, pipeline investment, and operating needs.

Bears Say

Persistent Losses And Cash BurnUltragenyx remains deeply loss-making despite growing revenue, and its negative operating and free cash flow show that losses require substantial funding. Continued cash consumption can restrict strategic flexibility and makes the timing of profitability especially important.

Negative Equity And Elevated Leverage RiskNegative equity and the reported debt spike materially weaken the balance sheet and reduce financial resilience. This can limit room to fund development internally, increase refinancing exposure, and make the company more sensitive to delays in cash-generating approvals or launches.

Late-stage Pipeline SetbackThe Aspire failure removes an important potential growth opportunity and raises questions about late-stage pipeline execution in a difficult genetic neurology setting. Reassessment may redirect R&D resources, while dependence on other clinical and regulatory programs remains material.

Ultragenyx Pharmaceutical News

Ultragenyx initiated with a Neutral at UBS

UBS initiated coverage of Ultragenyx (RARE) with a Neutral rating and $16 price target Two recent approvals, Fayuvi...

15d ago

RARE

Ultragenyx to sell Rare Pediatric Disease PRV for $203M

Ultragenyx (RARE) announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority...

15d ago

RARE

Ultragenyx to sell Rare Pediatric Disease Priority Review Voucher for $210M

Ultragenyx (RARE) announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority...

22d ago

RARE

Ultragenyx, Baylor Reach Settlement on DOJOLVI Patents

Ultragenyx Pharmaceutical ( ($RARE) ) has shared an announcement. On October 19, 2026, Ultragenyx Pharmaceutical Inc. and Baylor...

10d ago

RARE

Ultragenyx: Non-Dilutive Capital and Clinical Catalysts Underscore Buy Rating and Unchanged $25 Price Target

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ultragenyx Pharmaceutical, with...

15d ago

RARE

Ultragenyx Sells FDA Priority Review Voucher for Cash

Ultragenyx Pharmaceutical ( ($RARE) ) has shared an announcement. On October 8, 2026, Ultragenyx Pharmaceutical Inc. agreed to...

15d ago

RARE

Ultragenyx Monetizes FDA Priority Review Voucher Asset

Ultragenyx Pharmaceutical ( ($RARE) ) has issued an update. On October 6, 2026, Ultragenyx Pharmaceutical Inc. entered into...

22d ago

RARE

Ultragenyx Launches 10-Year Gene Therapy Monitoring Program for MPS IIIA

Ultragenyx Pharmaceutical, Inc. ($RARE) announced an update on their ongoing clinical study. The Mucopolysaccharidosis Type IIIA (MPS IIIA)...

27d ago

RARE

Ultragenyx: FDA Gene Therapy Progress and Upcoming Pivotal Readouts Support Buy Rating with Unchanged $25 Price Target

Ultragenyx Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

1M ago

RARE

Ultragenyx call volume above normal and directionally bullish

Bullish option flow detected in Ultragenyx (RARE) with 14,548 calls trading, 2x expected, and implied vol increasing almost...

1M ago

RARE

Ultragenyx price target raised to $18 from $16 at Evercore ISI

Evercore ISI raised the firm’s price target on Ultragenyx (RARE) to $18 from $16 and keeps an In...

1M ago

RARE

Ultragenyx price target raised to $35 from $32 at Barclays

Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating...

1M ago

RARE

Ultragenyx price target raised to $20 from $18 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Ultragenyx (RARE) to $20 from $18 and keeps an Equal...

1M ago

RARE

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

Abeona Therapeutics (ABEO) “congratulated” Ultragenyx Pharmaceutical (RARE) on the U.S. Food and Drug Administration, FDA, approval of FAYUVI,...

1M ago

ABEO

RARE

UP0 FAQ

What was Ultragenyx Pharmaceutical’s price range in the past 12 months?

Ultragenyx Pharmaceutical lowest stock price was €11.19 and its highest was €34.00 in the past 12 months.

What is Ultragenyx Pharmaceutical’s market cap?

Ultragenyx Pharmaceutical’s market cap is €1.52B.

When is Ultragenyx Pharmaceutical’s upcoming earnings report date?

Ultragenyx Pharmaceutical’s upcoming earnings report date is Nov 03, 2026 which is in 5 days.

How were Ultragenyx Pharmaceutical’s earnings last quarter?

Ultragenyx Pharmaceutical released its earnings results on Aug 04, 2026. The company reported -€0.807 earnings per share for the quarter, beating the consensus estimate of -€1.092 by €0.285.

Is Ultragenyx Pharmaceutical overvalued?

According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ultragenyx Pharmaceutical pay dividends?

Ultragenyx Pharmaceutical does not currently pay dividends.

What is Ultragenyx Pharmaceutical’s EPS estimate?

Ultragenyx Pharmaceutical’s EPS estimate is -0.99.

How many shares outstanding does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical has 98,588,875 shares outstanding.

What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?

Ultragenyx Pharmaceutical reported an EPS of -€0.807 in its last earnings report, beating expectations of -€1.092. Following the earnings report the stock price went up 5.899%.

Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?

Currently, no hedge funds are holding shares in DE:UP0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ultragenyx Pharmaceutical Stock Smart Score

Underperform

Fundamentals

Return on Equity

392.35%

Trailing 12-Months

Asset Growth

-3.24%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.

Ultragenyx Pharmaceutical (UP0) Earnings & Revenues

Historic Earnings Reports

UP0 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

Positive overall: the call highlighted record quarterly revenue, broad-based product growth (including Evkeeza +50% YoY), expanding patient counts across multiple geographies, improving cash consumption versus Q1, and clear near-term catalysts (two PDUFAs and a pivotal readout). Management articulated a credible path to profitability in 2027 with expense discipline and potential non-dilutive PRV monetization. Offsetting risks include a sizable operating loss and expense run-rate, reliance on binary regulatory outcomes, an unmet primary outcome for setrusumab requiring possible new trials, and readout/regulatory uncertainty for GTX-102, but these are framed as manageable and addressable within management's plan.View all DE:UP0 earnings summaries

UP0 Stock 12 Month Forecast

Average Price Target

€23.60

▲(9.60% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"€12","18":"€18","24":"€24","30":"€30","36":"€36"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.05788156,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€35.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.59665105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€23.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.38272064,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€14.38</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,18,24,30,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.095,14.784452427692308,16.473904855384617,18.163357283076923,19.852809710769233,21.54226213846154,23.231714566153848,24.921166993846157,26.610619421538463,28.30007184923077,29.989524276923078,31.678976704615387,33.368429132307696,{"y":35.05788156,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.095,13.902819311538462,14.710638623076923,15.518457934615384,16.326277246153847,17.134096557692306,17.94191586923077,18.74973518076923,19.55755449230769,20.365373803846154,21.173193115384613,21.981012426923073,22.78883173846154,{"y":23.59665105,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.095,13.194055433846154,13.293110867692308,13.392166301538461,13.491221735384617,13.59027716923077,13.689332603076924,13.788388036923077,13.887443470769231,13.986498904615384,14.08555433846154,14.184609772307693,14.283665206153847,{"y":14.38272064,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.37,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.52,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.53,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.095,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >